Clinical Trial Update: Study of Serine Supplementation to Protect Vision in MacTel [Phase 3]

View source ↗

Summary

Phase 3 study evaluating serine supplementation (L-Serine) to protect vision in Macular Telangiectasia Type 2 (MacTel); the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• L-serine (L-serine)

Snippet

Sponsor: The Lowy Medical Research Institute Limited | Conditions: Macular Telangiectasia Type 2 (MacTel) | Phase 3 | Status: NOT_YET_RECRUITING